Chairman of the Board:
- Pierre Rion
Non Executive Board Members:
- Alain Herrera
- Henri Tassenoy
- Marc Wauthoz
Executive Board Members:
- Marc Buyse, Founder and Chairman
- Damien Tremolet, Chief Executive Officer
- Joel Dequenne, Chief Financial Officer
Chairman of the Board:
Pierre H. Rion is a qualified Electronics and Computing Civil Engineer from the University of Liège. He is co-founder of the IRIS group (Euronext IRIS.BR) that he managed as President between 1992 and 2000.
He acted as board member of Azyx Pharma before it was acquired by IMS Health. He also sits on the boards of other Belgian companies, including EVS Broadcast, XDC Cinema, Parc Paradisio, Akkanto and Belrobotics. Acting as stand alone business angel in Wallonia, he is targeting technological companies in order to boost regional development.
Non Executive Board Members:
Alain Herrera, MD, is currently Consultant in Oncology. He has created Alain Oncology Consulting (AOC) in November 2008 after heading for ten years the Oncology business at Sanofi-aventis where he was successively Vice President responsible for Global Oncology Business Strategy and Development (2007-2008) and Head of Global Oncology Franchise (1998-2007) and contributed to the worldwide registration of two products: oxaliplatin (Eloxatin®) and rasburicase (Fasturtec®/Elitek®) as well as the Gastric and Head & Neck indications for docetaxel (Taxotere®). His previous responsibilities within Pharmaceutical industry include the roles of Chairman of Chiron Therapeutics Europe, Director of Chiron B.V, Corporate Vice President and Member of Management Council of Chiron Corporation and Managing Director at Pierre Fabre Oncology Laboratories. Besides these duties, Dr. Herrera has also been since 1991 Hematologist Consultant at Antoine Beclere Hospital and Beaujon Hospital. He also used to be Senior Resident, assistant to Prof. Pierre Boivin (Beaujon Hospital/University Paris VII). Dr. Herrera has published and lectured extensively as an invited speaker at national and international meetings on cancers. He has authored numerous manuscripts in addition to contributing to numerous review articles and book chapters. He is an active member of ASCO (American Society of Clinical Oncology) and ESMO (European Society of Medical Oncology) and serves on the Executive Committee of ESH (European School of Hematology) since 1985.
Henri Tassenoy is a Consultant in business management, trained by the Belgian Chamber of Accountants and "Bank" postgraduate. With approximately 12 years spent in the former General de Banque in various departments, Finance Management for 6 years of its subsidiary Capital Development : Former Synerfi. For 15 years, Henri Tassenoy has served as Independent Administrator of IDDI and companies active in various fields: advertising, real estate, wholesale trade. Henri provides consultancy in financial management, pre-acquisition auditing, restructuring and entrepreneurship.
Marc Wauthoz was born in Brussels and lives in Paris. With a degree in economy and management from the Solvay Business School of the University of Brussels, he was formerly a banker serving in Brussels, Luxembourg and France in various fields of an active bank: Corporate Banking and Regional Director for ING (ex-BBL) in Belgium, Administrator for the private BRED International Luxembourg Bank and Institutional Investor at the head of equity capital activities for the Groupe Banque Populaire in France. First to list on the New Market of the Paris Stock Exchange, and board member of the Nasdaq-Europe, he acquired a passion for the development and financing of High-Tech corporations. In 2002, Marc Wauthoz became Head of Strategy for Natexis, then Head of Research and Strategy for the Banque Fédérale des Banques Populaires, umbrella organization of the Groupe Banque Populaire. Instigator of the merger with the Groupe Caisses d'Épargne to form the second French banking group, he is Director of the General Secretariat of Natixis since the creation of this bank rated on the Euronext Paris market.
Executive Board Members:
Marc Buyse is founder of IDDI, Chairman of IDDI and Associate Professor of Biostatistics at the Universiteit Hasselt. He holds degrees in engineering and statistics from Brussels University (ULB), management from the Cranfield School of Management (Cranfield, UK) and a doctorate in biostatistics from Harvard University (Boston, MA). He was the recipient of several research fellowships in Belgium, the US and Japan. He was President of the International Society for Clinical Biostatistics, President of the Quetelet Society, and Fellow of the Society for Clinical Trials. He worked at the EORTC (European Organization for Research and Treatment of Cancer) in Brussels and at the Dana Farber Cancer Institute in Boston prior to founding IDDI in 1991. He has published extensively in the fields of clinical trial methodology, meta-analysis, statistical detection of fraud, validation of biomarkers and surrogate endpoints, and drug development in oncology and ophthalmology.
Damien Tremolet is Executive Director of IDDI. He holds degrees in information technology from Paris XI and management from ICHEC Brussels. He worked as IT Project Leader in the space, energy and railway industries before joining the pharmaceutical arena as IT Manager and Director of Operations for IDDI. He led Client Services in France and Belgium and set up an operational branch in Paris for Perceptive Informatics. He is keen to build long-term partnerships with clients and to promote the use of advanced methodology and integrated technology in clinical trials. Damien enjoys outdoor activities particularly trail running and sailing.
Joël Dequenne is Chief Financial Officer of IDDI. With a degree in economy and management from the Solvay Business School of the University of Brussels, he is mainly active in the market development of new technologies for chemical production and pharmaceutical research and has experience as Sales Manager, Corporate Manager and founder of companies involved in the implementation of new measurement technologies. He led a team specialized in the survey of scientific publications and patent databases using automatic mapping software. He also served in the marketing team of a major French private Contract Research Organization, Bertin & Cie, in charge of the chemical and pharmaceutical industries. He has been an active member of the European Industrial Research Management Association and was previously in charge of international sales and Group Product Manager for two French groups: Entreprise Minière et Chimique and Pechiney Ugine Kuhlmann. Joël has a passion for the history of art and especially for the "late gothic" period.